ArticleCureus2024
Comparative Analysis of Whole-Body Diffusion-Weighted Imaging and PET/CT in Metastasis Detection: A Prospective Study.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Tumor staging is essential for determining treatment strategies and predicting prognosis in cancer patients. Accurate imaging techniques are critical for staging, metastasis screening, treatment response assessment, and recurrence detection. Objective In this prospective study, we aimed to compare the sensitivity of whole-body diffusion-weighted imaging (WB-DWI) with positron emission tomography/computed tomography (PET/CT) in detecting metastases. Materials and methods Twenty-one patients with metastatic cancer disease confirmed by PET/CT examination were prospectively examined with WB-DWI. PET/CT scans were performed using 18-fluorodeoxyglucose (18F-FDG). To assess and localize metastatic lesions, each case was evaluated at 18 different sites, including the skeletal system, visceral areas, and lymph nodes. Lesions were localized and counted using both radiological modalities. Results Twenty-one patients with metastatic disease were included (12 men, 9 women; mean age 58 years). All patients underwent PET/CT followed by WB-DWI. The average interval between PET/CT and WB-DWI was 22.5 days. Of the 378 regions examined, PET/CT detected 68 metastases, while WB-DWI detected 64 metastases. Liver metastases were detected in 2 out of 3 patients by WB-DWI. WB-DWI demonstrated substantial agreement with PET/CT in detecting liver metastases (κ (Cohen's kappa) = 0.77, p < .001) and lung metastases (κ = 0.74, p < .001). All adrenal gland and soft tissue metastases were detected by WB-DWI, with perfect agreement (κ = 1, p < .001). WB-DWI detected 31 metastatic lymph nodes identified by PET/CT, also with perfect agreement (κ = 1, p < .001). Conclusion WB-DWI offers significant advantages over PET/CT, including reduced imaging time, no radiation exposure, and lower costs. WB-DWI demonstrates comparable sensitivity to PET/CT in metastasis screening, suggesting the potential to reduce PET/CT usage with further improvements in DWI parameters and MRI technology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.